Clinical Trial Update: A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer [Phase 1]

View source ↗

Summary

Phase 1 study investigating bemarituzumab (FPA144) with modified FOLFOX6 in gastric/gastroesophageal cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Cancer
• Gastrointestinal Cancer

Drugs mentioned

• Bemarituzumab (bemarituzumab)

Snippet

Sponsor: Five Prime Therapeutics, Inc. | Conditions: Gastrointestinal Cancer, Gastrointestinal Cancer Metastatic | Phase 1 | Status: COMPLETED | Results posted: 2023-01-27